ExeGi Pharma, a biopharmaceutical pioneer in live biotherapeutics, has commenced patient enrollment for its pivotal PROF Trial to test EXE-346, a new treatment targeting frequent bowel movements post ileal pouch-anal anastomosis surgery.

Pfizer Inc. has released an announcement that the European Commission has provided a conditional marketing approval for their product, ELREXFIO (elranatamab).

Vertex and CRISPR Therapeutics have declared that CASGEVY™ has been officially sanctioned by the FDA to combat sickle cell disease.

DAN-222 from Dantari has exhibited encouraging results in shrinking tumors for those suffering from advanced breast cancer that lacks the HER2 protein.

Ractigen Therapeutics, a pioneer in saRNA therapy, has submitted an Australian clinical trial application to commence a Phase I trial.

Century Therapeutics, a leader in iPSC-derived cell therapies for cancer and autoimmune diseases, announced FDA approval for their Phase 1 trial evaluating CNTY-101 in moderately to severely affected lupus patients unresponsive to at least two standard immunosuppressants.

Cocrystal Pharma has initiated the enrollment of the first participant in a Phase 2a clinical trial aimed at assessing the efficacy of the orally-administered CC-42344 for both pandemic and seasonal influenza A strains.

The Phase 3 study for Sarclisa® (isatuximab) delays disease progression in newly diagnosed multiple myeloma patients who are unsuitable for stem cell transplantation.

Wave Life Sciences has launched the first stage of treatment in its RestorAATion study, which assesses the pioneering RNA editing treatment, WVE-006, aimed at combatting Alpha-1 Antitrypsin Deficiency.

CatalYm Reports Promising Results for Phase 2a Trial with Visugromab Treating Late-Stage NSCLC and Bladder Cancer During the 2023 ESMO Immuno-Oncology Meeting.

Bolt Biotherapeutics Commences Phase 2 Clinical Trial Enrollment for BDC-1001 in HER2-Positive Breast Cancer Subjects Previously Administered Enhertu.

Coherus Showcases Early-Stage Study Results for its Novel IL-27-Specific Antibody, Casdozokitug, at ESMO's 2023 Immuno-Oncology Meeting.